Related Experiment Videos
Proarrhythmia: a paradoxic response to antiarrhythmic agents
P L McCollam1, R B Parker, K J Beckman
1Department of Pharmacy Practice, University of Illinois, Chicago 60612.
Pharmacotherapy
|January 1, 1989
Summary
Antiarrhythmic drugs can treat tachycardias but may cause dangerous arrhythmias like torsades de pointes. Understanding these proarrhythmic risks is crucial for safe antiarrhythmic drug selection and patient care.
Area of Science:
- Cardiology
- Clinical Pharmacology
- Electrophysiology
Background:
- Antiarrhythmic drugs are vital for managing tachycardias.
- These medications can paradoxically induce life-threatening arrhythmias, a phenomenon known as proarrhythmia.
- Electrophysiologic mechanisms like reentry and abnormal automaticity underlie proarrhythmia.
Purpose of the Study:
- To review the proarrhythmic effects of antiarrhythmic drugs.
- To differentiate the specific proarrhythmic profiles associated with different drug classes.
- To highlight the clinical implications and risk-benefit considerations of antiarrhythmic therapy.
Main Methods:
- Review of existing literature on antiarrhythmic drug-induced arrhythmias.
- Extrapolation of electrophysiologic mechanisms from reentry and abnormal automaticity models.
- Analysis of clinical presentations and risk factors for specific proarrhythmic events.
Main Results:
- All antiarrhythmic classes can cause proarrhythmia, including increased premature beats and ventricular tachycardia.
- Type Ia agents classically induce torsades de pointes, while Types Ib and Ic rarely do.
- Type Ic agents may precipitate sustained monomorphic ventricular tachycardia in high-risk patients; amiodarone can cause diverse, prolonged arrhythmias.
Conclusions:
- Proarrhythmia is a common, paradoxical side effect of antiarrhythmic drugs.
- Distinct proarrhythmic profiles exist for different antiarrhythmic drug classes.
- Clinicians must carefully weigh risks and benefits when prescribing antiarrhythmic therapy.